Instrument Inactif

Communiqués Lannett Company, Inc.

Actions

LCI

US5160122009

Produits pharmaceutiques

Communiqués

19/05	FDA Approves Lannett, Lanexa Biologics, And Sunshine Lake Pharma’s Interchangeable Insulin Glargine Biosimilar	AQ
03/05/23	LANNETT COMPANY, INC. FILES PREPACKAGED CHAPTER 11 CASES TO SIGNIFICANTLY STRENGTHEN FINANCIAL POSITION	PR
01/05/23	Lannett Company, Inc. Enters Into Restructuring Support Agreement	PR
20/04/23	NYSE TO SUSPEND TRADING IMMEDIATELY IN LANNETT COMPANY, INC. (LCI) AND COMMENCE DELISTING PROCEEDINGS	PR
14/04/23	LANNETT CO INC : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	AQ
04/04/23	LANNETT CO INC : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
04/04/23	LANNETT SHARES UPDATE	PR
07/02/23	Lannett : Modification to Rights of Security Holders - Form 8-K	PU
07/02/23	LANNETT CO INC : Material Modification to Rights of Security Holders, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	AQ
02/02/23	LANNETT CO INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	AQ
01/02/23	Lannett: Fiscal Q2 Earnings Snapshot	AQ
01/02/23	LANNETT REPORTS IMPROVED FISCAL 2023 SECOND QUARTER FINANCIAL RESULTS; RAISES FULL-YEAR GUIDANCE	PR
26/01/23	Lannett : Submission of Matters to a Vote of Security Holders - Form 8-K	PU
26/01/23	LANNETT CO INC : Submission of Matters to a Vote of Security Holders (form 8-K)	AQ
25/01/23	LANNETT ANNOUNCES 1 FOR 4 REVERSE STOCK SPLIT	PR
25/01/23	LANNETT TO REPORT FISCAL 2023 SECOND-QUARTER FINANCIAL RESULTS, HOST CONFERENCE CALL ON WEDNESDAY, FEBRUARY 1	PR
04/01/23	LANNETT PROVIDES DEVELOPMENT UPDATE ON BIOSIMILAR INSULIN PRODUCTS	PR
16/12/22	LANNETT CO INC : Costs Associated with Exit or Disposal Activities, Material Impairments (form 8-K)	AQ
14/11/22	LANNETT CO INC : Entry into a Material Definitive Agreement (form 8-K)	AQ
07/11/22	LANNETT ANNOUNCES PATENT LICENSES FOR THE PEN INJECTOR DELIVERY DEVICE TO BE USED FOR ITS INSULIN GLARGINE AND INSULIN ASPART DEVELOPMENT PROGRAM	PR
03/11/22	LANNETT CO INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	AQ
02/11/22	Lannett: Fiscal Q1 Earnings Snapshot	AQ
02/11/22	LANNETT REPORTS BETTER THAN EXPECTED FINANCIAL RESULTS FOR FISCAL 2023 FIRST-QUARTER; REITERATES FULL-YEAR GUIDANCE	PR
26/10/22	LANNETT TO REPORT FISCAL 2023 FIRST-QUARTER FINANCIAL RESULTS, HOST CONFERENCE CALL ON WEDNESDAY, NOVEMBER 2	PR
24/10/22	LANNETT RECEIVES FDA APPROVAL TO MANUFACTURE NUMBRINO AT SEYMOUR PLANT	AQ